Designing for Differentiation: Why We Need Highly Specific Diagnostics for a COVID-19 Vaccine
Assessment of vaccine-induced immune responses in clinical trials will require highly specific diagnostic assays to ensure safety. This blog was originally published on Clinical Lab Manager. The Vaccine Race Vaccines are the most effective means of preventing...
An Early Look at Vaccines for COVID-19
In the first of a three-part series on the design, immunology and manufacture of COVID-19 vaccines, we take an early look at the major technologies under development and weigh-up the challenges these vaccines will face in reaching late-phase clinical trials. Why We...
Why We Need Antigen and Antibody Tests for COVID-19
RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...
Novel Coronavirus Antigens Now Available
The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines. S1 Glycoprotein S2...